Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Kinase fusions, Receptor tyrosine kinase/growth factor signaling
Protein [2]
BDNF/NT-3 growth factors receptor
Synonyms [1]
trk-B, GP145-TrkB, EIEE58, TRKB, OBHD, DEE58

Neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) is a gene that encodes a protein in the neurotrophic tyrosine receptor kinase (NTRK) family that participates in the MAP kinase signaling pathway. Fusions, missense, nonsense, and silent mutations are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

NTRK2 is altered in 1.43% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and melanoma having the greatest prevalence of alterations [3].

NTRK2 GENIE Cases - Top Diseases

The most common alterations in NTRK2 are NTRK2 Mutation (1.25%), NTRK2 Loss (0.04%), NTRK2 Fusion (0.05%), NTRK2 Amplification (0.04%), and NTRK2 V606I (0.04%) [3].

NTRK2 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of NTRK2 in Diseases

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Acute Lymphoblastic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Melanoma +

Colorectal Carcinoma +

Breast Carcinoma +

Acute Myeloid Leukemia +

Congenital Mesoblastic Nephroma +

Infantile Fibrosarcoma +

Anaplastic Large Cell Lymphoma +

Lung Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Non-Hodgkin Lymphoma +

Lymphoma +

Mixed Phenotype Acute Leukemia +

Myelodysplastic Syndromes +

Malignant Uterine Neoplasm +

Malignant Colorectal Neoplasm +

Bladder Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Lung Adenocarcinoma +

Gallbladder Carcinoma +

Gastric Adenocarcinoma +

Desmoplastic Small Round Cell Tumor +

Squamous Cell Lung Carcinoma +

Head And Neck Carcinoma +

Malignant Glioma +

Chronic Myelomonocytic Leukemia +

Esophageal Squamous Cell Carcinoma +

Central Nervous System Neoplasm +

Ovarian Carcinoma +

Prostate Carcinoma +

Malignant Ovarian Neoplasm +

Cervical Carcinoma +

Soft Tissue Sarcoma +

Bile Duct Carcinoma +

Pancreatic Carcinoma +

Kidney Carcinoma +

Acute Leukemia +

B-Cell Lymphoblastic Lymphoma +

Bronchogenic Carcinoma +

Chronic Myeloid Leukemia +

Histiocytic And Dendritic Cell Neoplasm +

Lymphoblastic Lymphoma +

Mixed Phenotype Acute Leukemia, B/Myeloid, NOS +

Mixed Phenotype Acute Leukemia, T/Myeloid, NOS +

Multiple Myeloma +

Secondary Acute Myeloid Leukemia +

Secretory Breast Carcinoma +

T-Cell Acute Lymphoblastic Leukemia +

T-Cell Lymphoblastic Lymphoma +

Therapy-Related Acute Myeloid Leukemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.